Your browser doesn't support javascript.
loading
An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA).
Katz, Micah; Newmark, Rebecca L; Aronstam, Alison; O'Grady, Niamh; Strome, Sara; Rafie, Sally; Karlin, Jennifer.
Afiliación
  • Katz M; University of California San Francisco School of Medicine, San Francisco, CA, USA.
  • Newmark RL; University of California San Francisco School of Medicine, San Francisco, CA, USA.
  • Aronstam A; University of California San Francisco School of Medicine, San Francisco, CA, USA.
  • O'Grady N; University of California San Francisco School of Pharmacy, San Francisco, CA, USA.
  • Strome S; University of California San Francisco School of Pharmacy, San Francisco, CA, USA.
  • Rafie S; Birth Control Pharmacist, San Diego, CA, USA.
  • Karlin J; University of California Davis Department of Family and Community Medicine, Sacramento, CA, USA. Electronic address: jkarlin@ucdavis.edu.
Contraception ; 102(6): 392-395, 2020 12.
Article en En | MEDLINE | ID: mdl-32931811
OBJECTIVE: To describe the implementation and results of a proactive patient outreach project to offer self-administered, depot medroxyprogesterone (DMPA) subcutaneous (SC) to interested patients at a California safety-net clinic following expanded state Medicaid coverage. STUDY DESIGN: We contacted non-pregnant patients at an urban, safety-net hospital-based primary care clinic who had been prescribed DMPA intramuscular (IM) in the past year to gauge interest in self-administered DMPA-SC. Interested patients received a prescription for DMPA-SC and a telehealth appointment with a clinic provider to learn self-injection. We recorded patient interest in DMPA-SC, completed appointments, and completed first injections. We conducted initial outreach in May, 2020 and recorded appointment attendance and completed injections through August, 2020. RESULTS: Of 90 eligible patients (age 17-54), we successfully contacted and discussed DMPA-SC with 70 (78%). Twenty-six (37%) patients expressed interest in DMPA-SC and scheduled telehealth appointments to learn to self-administer the medication. Fifteen (58%) of those interested (21% of the total) successfully self-injected DMPA-SC. Of the 44 (63%) patients not interested in DMPA-SC, the three most common reasons were fear of self-injection (n = 23 [52%]), wanting to stop DMPA (n = 11 [25%]), and satisfaction with DMPA-IM (n = 6 [14%]). CONCLUSION: There is interest in and successful initiation of self-administered DMPA-SC among patients at an urban safety net hospital-based primary care clinic who have used DMPA-IM in the last year. IMPLICATIONS: Our data provide evidence for the interest and successful first injection rate after offering self-administered DMPA-SC to patients on DMPA-IM. Expanding coverage of self-administered DMPA-SC could increase patient-centeredness and accessibility of contraception as well as reduce patient anxiety around COVID-19 transmission without losing contraceptive access.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Aceptación de la Atención de Salud / Telemedicina / Acetato de Medroxiprogesterona / Agentes Anticonceptivos Hormonales / Anticoncepción Hormonal Límite: Adolescent / Adult / Female / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Contraception Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Aceptación de la Atención de Salud / Telemedicina / Acetato de Medroxiprogesterona / Agentes Anticonceptivos Hormonales / Anticoncepción Hormonal Límite: Adolescent / Adult / Female / Humans / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Contraception Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos